In a report issued on February 27, Marc Goodman from Leerink Partners maintained a Buy rating on Biohaven Pharmaceutical Holding Co (BHVN – Research Report), with a price target of $150.00. The company’s shares closed last Monday at $118.71.
According to TipRanks.com, Goodman is a 3-star analyst with an average return of 0.9% and a 45.6% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Intra-Cellular Therapies, and Satsuma Pharmaceuticals.
Currently, the analyst consensus on Biohaven Pharmaceutical Holding Co is a Strong Buy with an average price target of $158.43, implying a 32.7% upside from current levels. In a report issued on February 21, Mizuho Securities also maintained a Buy rating on the stock with a $144.00 price target.
Biohaven Pharmaceutical Holding Co’s market cap is currently $8.19B and has a P/E ratio of -9.03.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.
Read More on BHVN:
- Reata Pharmaceuticals (RETA) Gets a Hold Rating from Leerink Partners
- Analysts Have Conflicting Sentiments on These Healthcare Companies: ImmunoGen (IMGN), uniQure (QURE) and Myovant Sciences (MYOV)
- Robert W. Baird Reaffirms Their Buy Rating on Dutch Bros Inc (BROS)
- Marriott International Updates 1 Key Risk Factor
- ZipRecruiter (ZIP) Receives a Rating Update from a Top Analyst